First Tracks Biotherapeutics, Inc.
corporate_fare Company Profile
First Tracks Biotherapeutics, Inc. (NASDAQ:TRAX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 11 items for TRAX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-03, rated 7/10. Across its 11 most recent items scored 7 or higher, the top rating is 9/10, with 6 rated 8 or above. Recent SEC coverage for TRAX spans 8-K, 424B3, 10-Q, S-1.
Recent high-impact activity:
- Q3 Net Loss Narrows to $31.4M as First Tracks Lays Out 2027 Data Calendar
- First Tracks Raises $200M in Private Placement at $32.75/Share
- First Tracks Raises $200M at $32.75/Share, a 6% Discount to Last Close
- ANB033 Hits All Endpoints in Celiac Trial, First-Ever Symptom and Histology Win
- First Tracks Q2: FDA Fast Track for ANB033, Cash Runway Extended to Q2 2028
Short Interest & Short Volume
6.52 days to coverFINRA reported short interest of 5,056,413 shares in TRAX as of the October 30, 2026 settlement, a 27.3% decrease from the prior period — about 6.5 days to cover at its recent average daily volume. On November 20, 2026, 53.0% of TRAX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for TRAX, detected from its recent SEC filings · based on capital-structure filings through 2026-10-15.
Private Placement of 6.1M Shares · Dilution of About 17%
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →